Objectives Evaluate the differences with densitometry after 2 years of treatment in patients with breast cancer and a high risk fracture. Methods A 2 year duration longitudinal study was done in patients diagnosed with breast cancer sent to the Rheumatology Osteoporosis Unit in Hosptial d’Ontinyent, and required supplements of calcium and vitamin D ± bisphosphonates after a risk fracture study. A register and description of the socio-demographic data was done, as well as the characteristics of the breast tumor, the risk factors of osteoporosis and fragile fractures, the definite diagnosis and the treatment initiated in these patients. Differences between the mean values obtained in the mineral bone density of lumbar, total femoral, and femoral neck, were evaluated with the t-student study. The statistic system employed was SPSS 17.0. Results 41 patients were studied, with an average age of 59 years old (37 - 79 years).All of them had a unilateral breast cancer, while none had metastases.The treatments received were: radical mastectomy (61%), radiotherapy (61%), chemotherapy (78%), hormonotherapy (29%), tamoxifen (51%), GnRH analogues (12%) and aromatase inhibitors (88%). Risk factors for osteoporosis are shown on table 1. High risk osteoporosis was diagnosed in 3 patients (7.3%), osteoporosis in 15 patients (36.6%) and osteopenia in 23 patients (56.1%).In spinal x-rays, 49 patients had ≥1 vertebral collapse and 7 of them ≥1 vertebral fracture.Treatment with supplements of calcium and vitamin D was initiated in all patients, and bisphosphonates (either oral or i.v.) in 34 patients, as follow: ibandronate (in 13), risedronate (in 15), alendronate (in 5) and zoledronate (in the remaining one).After 2 years of follow-up, no patient had developed metastases and 82.9% continued with aromatase inhibitors. No patient suffered new vertebral collapse or fracture, and only 1 patient suffered from other fractures. After a 2 year treatment of osteoporosis, 95.1% of the patients continued with the same treatment, and only 2 patients had abandoned it. Results obtained from densitometry pre-treatment and after 2 year treatment, as well as statistical differences by applying t-student test, are shown on table 2. Table 1. Risk factors for osteoporosis in patients with breast cancer and fragile risk fracture Factorn%Factorn% Early menopause1128.2Medical History hip fracture00 Induced menopause1741.5Medical History other fractures37.3 BMI <22512.5Family Diseases osteoporosis1024.4 Medical History ≥1 fracture819.5Family Diseases hip fracture1126.8 Medical History vertebral fractures12.4Corticosteroid Treatment24.9 Medical History Colles fracture49.8Smoking24.9 Table 2. Values obtained from bone densitometry (mean, standard deviation) and statistical differences DXALumbarFemoral NeckFemoral Total DMO basal0.933±0.080.832±0.100.870±0.11 DMO 2 years0.959±0.090.850±0.100.883±0.10 p0.0150.0160.016 Conclusions Patients with breast cancer that require initiating treatment for fragile risk fracture present good treatment compliance. Tr...

No abstract

Objectives Describe the prevalence of cardio and brainvascular diseases as well as the risk factors in patients with inflammatory espondiloarthritis in our health area. Methods Transversal study of a cohort of patients diagnosed of espondiloarthritis(AS:modified New York criteria;Psoriasic arthritis: ESSG criteria) in Manises’ Hospital Rheumatology Unit,from the 1st of July 2011 until the 15th of November 2011.We registered different variables as socio-demographic,disease,cardiovascular risk factors,physical examination and serum levels.The SPSS Statistic version 20 was used for calculating statistics. Results 60 patients were included(41 men;19 women)with an average age of 47±12 years old.39 patients were diagnosed of AS while 21 were diagnosed of PsoA.They presented axial symptomes in 39, articular in 19 and 2 patients with both localizations affected.The average evolution time of the disease was of 8.8±6 years.55% of the patients were HLA-B27+,10% had suffered from at least one episode of uveitis,28% cutaneous and or nail psoriasis and 7% had frequent episodes of diarrhea.The C Reactive Protein average levels were 5.6±8.43 mg/dl while ESR levels were of 9.5±9.84.According to therapy,1 patient wasn’t taking medication,10 patients were taking NSAIDs(including COX-2)as monotherapy,24 patients had classic DMARDs and 25 had anti-TNFalpha.In the following table the prevalences of the main cardiovascular risk factors of the patients from our cohort are shown.The average BMI was of 28.1 + 4, presenting indexes of overweight or obesity in 80% of the patients.The mean abdominal perimeter was of 93.1 + 14, being in 30% of men >102 cm and in 60% of the women >88 cm. Table of the prevalences of the main cardiovascular risk factors of the patients from our cohort: CVRF% (n) Sedentarism45 (n 27) Smoking22 (n 13) Obesity27 (n 16) Hypertension35 (n 21) Glucose intolerance12 (n 7) Diabetes Mellitus15 (n 9) Dislipemia30 (n 18) Hypercholesterolemia27 (n 16) Hypertriglyceridemia20 (n 12) Hyperuricemia12 (n 7) Metabolic Syndrome25 (n 15) Medical History – Heart Disease7 (n 4) Medical History – Stroke2 (n 1) Medical History – Renal failure7 (n 4) Family – Heart disease17 (n 10) Family Diseases – Stroke7 (n 4) Conclusions In patients with chronic inflammatory espondiloarthropathies in our health area there is a high prevalence of classic cardiovascular risk factors, specially sedentarism and overweight. However, they show a low prevalence of cardiovascular events, probably due to the mean age of our patients. Studying the prevalences of the cardiovascular risk factors in patients with espondiloarthritis, which include antropometric, blood pressure and lab measurements, allow us to determine the real risk prevalence as well as to define new strategies of cardiovascular prevention. Disclosure of Interest None Declared